Discover
llllllllll Lynparza (olaparib) / Merck (MSD), AstraZenecaLynparza: Regulatory decision in EU for 1L ovarian cancer (based on PAOLA trial) in H2 2020 (AstraZeneca) - Aug 21, 2020 - Post H1 Roadshow, Oslo: Regulatory decision in EU for 2L prostate cancer in H2 2020 [Screenshot]llllllllll Lynparza (olaparib) / Merck (MSD), AstraZenecaDCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer (Medicircle) - Aug 20, 2020 - "Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer...The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.The tablets are a patented product of the AstraZeneca group..."llllllllll Aybintio (bevacizumab biosimilar) / Samsung, MundipharmaSamsung Bioepis Receives European Commission Approval for AYBINTIO (Bevacizumab) (GlobeNewswire) - Aug 20, 2020 - "Samsung Bioepis Co., Ltd....announced that the European Commission (EC) has granted marketing authorization for AYBINTIO® (bevacizumab) for the treatment of the same types of cancer as reference bevacizumab, including metastatic carcinoma of the colon or rectum (mCRC), metastatic breast cancer (mBC), non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer (mRCC), epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer. "
